Fixed leasing agreement Pages Sold Revenue (1) (2) 30,000 45,000 60,000 75,000 90,000 30,000 $.20 = $ 6,000 45,000 $.20 = $ 9,000 60,000 $.20 = $ 12,000 75,000 $.20 = $ 15,000 90,000 $.20 = $ 18,000 Variable Costs (3) 30,000 $.15 = $4,500 45,000 $.15=$6,750 $1,500 Operati ng Income (Loss) (5) = (2) (3) (4) $ 0 $1,500 $ 750 0.20 150 60,000 $.15=$9,000 $1,500 $1,500 0.20 300 75,000 $.15=$11,25 0 90,000 $.15=$13,50 0 $1,500 $2,250 0.20 450 $1,500 $3,000 0.20 600 3-47 Fixed Costs (4) Prob abi lity (6) Expected Operating Income (7)=(5) (6 ) 0.20 $ 0 EA Expected value of fixed leasing agreement $1,500 Commission-based leasing agreement: Pages Variable Sold Revenue Costs (1) (2) (3) 30,000 30,000$.20 = $ 6,000 30,000 $.17 = $5100 45,000 45,000$.20=$ 9,000 45,000 $.17=$,7,650 60,000 60,000$.20 = $ 12,000 60,000 $.17 = $10,200 75,000 75,000$.20=$ 15,000 75,000 $.17=$12,750 90,000 90,000$.20=$ 18,000 90,000 $.17=$15,300 Expected value of commission based agreement Operating Income (4) = (2) (3) $900 $1,350 $1,800 $2,250 $2,700.00 Probabil ity (5) 0.20 0.20 0.20 0.20 0.20 Expected Operati ng Income (6)=(4)(5) $ 180 270 360 450 540 $1,800 Sunshine should choose the commission-based agreement because the expected value is higher than under the fixed cost leasing agreement

The drug suppresses appetite

Key Points Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) signalling plays a major part in fuel metabolism and in the regulation of body composition Obesity, particularly abdominal obesity, exerts a strong negative effect on the spontaneous pulsatile secretion of GH, which has been associated with adverse metabolic complications GH administration in individuals with abdominal obesity reduces visceral and total body adipose tissue mass, as well as levels of total and LDL cholesterol Increasing the endogenous pulsatile GH secretion in individuals with obesity has metabolic effects similar to those obtained by the administration of exogenous GH but potentially with less adverse effects on glucose metabolism Mouse models with altered GH signalling provide a useful means for a comparative analysis of GH action in obesity The role of the GH/IGF-1 axis in modifying obesity must be assessed in light of newly emerging data that highlight the complexity of adipose tissue This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 183,71 per year only 15,31 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF

In ophthalmology, the clinical development of RGN-259 (topical thymosin beta-4 formulation) represents the most advanced therapeutic application, with Phase II/III trials for dry eye disease